Affinia Therapeutics Appoints Petra Kaufmann, MD, as Chief Medical Officer

EFFECTIVE DATE:

Chartwell Partners is pleased to announce the recruitment of Petra Kaufmann, MD, as Chief Medical Officer for Affinia Therapeutics, a next generation gene therapy company utilizing its proprietary platform to engineer novel vectors and gene therapies for rare and non-rare diseases. Dr. Kaufmann brings to Affinia substantial expertise in neuroscience translational medicine and clinical development from the biopharmaceutical industry, academia, and the National Institutes of Health. She played a leadership role in the development of Zolgensma® for SMA while with AveXis and Novartis Gene Therapies, most recently serving as Senior Vice President and Head, Clinical Development, Analytics and Translational Medicine.

 

For more information on Dr. Kaufmann and Affinia’s premier leadership team, please visit: https://www.affiniatx.com/pdf/Leadership-Press-Release.pdf.